KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Research & Development (2016 - 2025)

Historic Research & Development for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $13.3 million.

  • Inovio Pharmaceuticals' Research & Development fell 2882.66% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.8 million, marking a year-over-year decrease of 2895.35%. This contributed to the annual value of $75.6 million for FY2024, which is 1275.57% down from last year.
  • As of Q3 2025, Inovio Pharmaceuticals' Research & Development stood at $13.3 million, which was down 2882.66% from $14.5 million recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Research & Development registered a high of $92.3 million during Q4 2021, and its lowest value of $12.9 million during Q4 2024.
  • In the last 5 years, Inovio Pharmaceuticals' Research & Development had a median value of $23.7 million in 2023 and averaged $33.8 million.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Research & Development surged by 25091.19% in 2021 and then plummeted by 5903.82% in 2023.
  • Over the past 5 years, Inovio Pharmaceuticals' Research & Development (Quarter) stood at $92.3 million in 2021, then crashed by 54.37% to $42.1 million in 2022, then plummeted by 59.04% to $17.3 million in 2023, then fell by 25.31% to $12.9 million in 2024, then increased by 3.48% to $13.3 million in 2025.
  • Its last three reported values are $13.3 million in Q3 2025, $14.5 million for Q2 2025, and $16.1 million during Q1 2025.